What is follicular hyperplasia?
Follicular hyperplasia is a benign white blood cell disorder where lymph nodes increase due to an increased number of germ centers, areas where cells mature and differentiate to supply the lymphatic system with new white blood cells. There may be a number of different causes and the physician may provide treatment, if necessary, after evaluating the patient and learn more about the condition. It is important to realize that follicular hyperplasia is not a cancer such as Hodgkin's lymphoma, but the doctor may have to test cancer to exclude it, only in case.
patients usually develop in response to infection or inflammation. Lymph nodes swell and increase not only because they collect more detritus when the immune system kicks into action, but because the germ centers can proliferate to meet the needs of the immune system. If a doctor takes a biopsy, he sees a range of many types of lymphatic cells along with more germistrants than usual, including deep in lymphatia node. In a cancer lymph node, the pathologist would expect to see only one kind of cell, which is the result of a cancer cell that spoils and replicates out of control. A mixture of many types of cells indicates benign growth and will not spread to other lymph nodes or adjacent tissues.
cases of follicular hyperplasia can be associated with lymphedema where limbs swell liquid. This happens when the lymphatic system cannot clean the liquid fast enough and starts to connect, especially in the legs and feet. The doctor may recommend compression clothing to prevent the accumulation and pushing of the existing fluid slowly back into circulation so that the body can eliminate it. Further treatment may include dietary changes and medication.
When a doctor feels swollen lymph nodes, he will note all other systems and may apply for some medical testing to learn more about the cause. U follicular hyPerplasia wants to make sure that any malignancy is excluded, as treatment will vary depending on the cause. Diagnostic testing will reduce the risk of administering poor treatment recommendations that could lead to the inability to treat malignancy in the early stages where it would still be manageable and the patient would have a good prognosis.